Prelude Therapeutics
2 known investors
Prelude Therapeutics develops precision oncology medicines, including selective KAT6A degraders, mutant-selective JAK2 inhibitors, and degrader antibody conjugates for cancer treatment. The company focuses on clinically validated targets with high unmet medical needs in oncology.
AI & Machine LearningBiotechMedical Devices
Investors · 2
In the news
- Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Rating of “Hold” by Brokerages - Daily Politicaldailypolitical.com · 2026
- Citizens reiterates Prelude Therapeutics stock rating on IND filing By Investing.cominvesting.com · 2026
- Jefferies raises Prelude Therapeutics stock price target on pipeline progress By Investing.comca.investing.com · 2026
- H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.cominvesting.com · 2026
- Prelude Therapeutics raises $60 million in new funding round - Division of Small Business - State of Delawarebusiness.delaware.gov · 2019
- Prelude Therapeutics Raises $60M in Series B Funding - FinSMEsfinsmes.com · 2019